Arrowhead Pharmaceuticals Inc (ARWR)
Debt-to-capital ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 160,407 | 271,343 | 364,830 | 446,772 | 377,039 | 398,520 | 453,927 | 452,266 | 372,560 | 408,822 | 436,890 | 445,549 | 454,472 | 461,779 | 493,140 | 494,119 | 500,084 | 244,591 | 226,225 | 201,195 |
Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $160,407K)
= 0.00
The debt-to-capital ratio for Arrowhead Pharmaceuticals Inc. has been consistently reported as 0.00 across all quarters for the years 2022 and 2023. This indicates that the company has not used any debt to finance its operations relative to its total capital structure during these periods. A debt-to-capital ratio of 0.00 suggests that the company relies solely on equity financing or has minimal debt obligations compared to its equity. While a low or zero debt-to-capital ratio can be a positive sign of financial stability and lower risk, it's essential to consider other financial metrics and factors to gain a more comprehensive understanding of Arrowhead Pharmaceuticals' overall financial health and performance.
Peer comparison
Dec 31, 2023